LUGPA Annual Meeting | Conference

Dr. Shore on the Importance of Genetic Testing in Prostate Cancer

November 11th 2022

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

Role of PSMA-PET Expands in the Treatment of Prostate Cancer

November 11th 2022

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Shore Unpacks Treatment Advances for Patients With Urologic Cancers

November 11th 2022

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

Robotic Surgery Is Milestone Advancement for Prostate Cancer Treatment

January 23rd 2017

David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.

Dr. Albala on the Benefits of Robotic Surgery in Prostate Cancer

January 12th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses the benefits associated with robotic surgery in the treatment of patients with prostate cancer.

Experts Provide Tips on Setting Up a Successful Community-Based Clinical Trials Program

November 8th 2016

Clinical research in private practice is thriving and the future is bright.

LUGPA Will Create Bundled Payment Models for Prostate Care

November 8th 2016

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

Expert Emphasizes Impact of Robotic Surgery in Field of Prostate Cancer

November 8th 2016

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment

November 7th 2016

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Dr. Buffington on The Use of Fusion MRI in Prostate Cancer

November 7th 2016

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

Potential for Neoadjuvant Immunotherapy in Bladder Cancer Is Wide Open, Expert Says

November 7th 2016

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models

November 7th 2016

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Dr. David Albala on The Role of Robotic Surgery in Prostate Cancer

November 6th 2016

Systemic Immunotherapy Use Expanding Rapidly in Bladder Cancer

November 6th 2016

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

Novel Therapies Offer Hope for BCG-Unresponsive Bladder Cancer

November 5th 2016

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.

Bladder Cancer Biomarkers Aid in Diagnosis, Monitoring

November 5th 2016

When it comes to the burgeoning arena of biomarkers in bladder cancer, the value proposition is compelling, although the utility and costs need to be better defined, according to Badrinath Konety, MD, MBA.

Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder Cancer

November 5th 2016

Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.

Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer

November 5th 2016

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.

Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer

November 4th 2016

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.